Myocardial Infarction Drugs: 2025 ACS Guideline, Reperfusion and Secondary Prevention

Updated 10 November 2026. Educational content only; individual clinical care requires current local guidelines and product labeling. Overview Myocardial infarction (MI) is a time-critical manifestation of acute coronary syndrome (ACS). ST-elevation myocardial infarction (STEMI) and non-ST-elevation ACS require rapid ECG assessment, troponin testing and appropriate reperfusion/risk stratification. Pharmacotherapy complements—not replaces—urgent percutaneous coronary intervention (PCI) when…

Read Full News

Antianginal Drugs: Nitrates, Beta Blockers, Calcium Blockers and Ranolazine

Updated 10 November 2026. Educational content only; individual clinical care requires current local guidelines and product labeling. Overview Angina is discomfort or an anginal equivalent due to myocardial oxygen supply–demand mismatch. In chronic coronary disease, antianginal drugs reduce symptoms, while separate therapies—lipid lowering, antithrombotics when indicated, smoking cessation and risk-factor control—reduce cardiovascular events. Angina caused…

Read Full News

Vasodilator Pharmacology: Nitrates, Hydralazine, Minoxidil and Clinical Safety

Pharmacology education review. Updated 10 November 2026. This is not an individual prescribing protocol; follow current local guidelines and product labeling. Overview Vasodilators reduce vascular smooth-muscle tone through multiple molecular targets. Their effects on venous capacitance, systemic arterial resistance and pulmonary vascular resistance differ, making a drug appropriate for one condition but harmful in another….

Read Full News

Calcium Channel Blockers: Dihydropyridines, Verapamil, Diltiazem and Safety

Pharmacology education review. Updated 10 November 2026. This is not an individual prescribing protocol; follow current local guidelines and product labeling. Overview Calcium channel blockers (CCBs) inhibit L-type voltage-gated calcium channels and are used for hypertension, chronic angina and selected arrhythmias. Tissue selectivity distinguishes predominantly vascular dihydropyridines from non-dihydropyridines with substantial cardiac conduction effects [1,2]….

Read Full News

RAAS Modulators: ACE Inhibitors, ARBs, Renin Inhibitors and Mineralocorticoid Antagonists

Educational pharmacology review updated 10 November 2026. This material does not replace clinical evaluation, local licensing rules or patient-specific prescribing guidance. Clinical overview The renin–angiotensin–aldosterone system (RAAS) maintains blood pressure, extracellular volume and potassium homeostasis. Pharmacologic blockade is central to treatment of hypertension, heart failure and albuminuric chronic kidney disease (CKD). These drug families act…

Read Full News

Drugs of Misuse and Substance Use Disorders: Mechanisms, Overdose and Evidence-Based Treatment

Educational pharmacology review updated 10 November 2026. This material does not replace clinical evaluation, local licensing rules or patient-specific prescribing guidance. Overview Psychoactive substances can produce intoxication, tolerance, withdrawal and substance use disorders. Diagnosis considers impaired control, continued use despite harm and other clinical criteria—not exposure or physical dependence alone. Person-centred, non-stigmatizing language and timely…

Read Full News

CNS Stimulants and Nootropics: ADHD Pharmacotherapy, Wakefulness Agents and Safety

Educational pharmacology review updated 10 November 2026. This material does not replace clinical evaluation, local licensing rules or patient-specific prescribing guidance. Overview Central nervous system stimulants have established clinical uses, notably attention-deficit/hyperactivity disorder (ADHD) and selected sleep-wake disorders. The popular term ‘nootropic’ is not a single pharmacological or regulatory class, and claims of meaningful cognition…

Read Full News

Alzheimer Disease Drugs: Cholinesterase Inhibitors, Memantine and Anti-Amyloid Therapy in 2026

Educational pharmacology review updated 10 November 2026. This material does not replace clinical evaluation, local licensing rules or patient-specific prescribing guidance. Overview Alzheimer disease (AD) is a progressive neurodegenerative illness associated with amyloid-β pathology, tau changes and loss of neuronal networks. Drug treatment includes symptomatic cognitive therapies and, for carefully selected patients with early symptomatic,…

Read Full News

Parkinsonism Drugs: Levodopa, Dopamine Agonists, MAO-B and COMT Inhibitors

Educational pharmacology review updated 10 November 2026. This information does not replace a patient-specific clinical evaluation or current local prescribing guidance. Overview Parkinsonism describes bradykinesia with tremor, rigidity or other features; idiopathic Parkinson disease must be distinguished from drug-induced and atypical syndromes. Medicines primarily improve motor symptoms but do not yet reliably stop neurodegeneration. Treatment…

Read Full News

Opioid Analgesics: Receptor Pharmacology, Safer Prescribing and Overdose Prevention

Educational pharmacology review updated 10 November 2026. This information does not replace a patient-specific clinical evaluation or current local prescribing guidance. Overview Opioids are analgesics for selected moderate-to-severe acute pain, cancer-related pain and palliative care, and for carefully selected chronic pain cases when benefits outweigh harms. For many common subacute and chronic pain conditions, nonopioid…

Read Full News